Study aim: Evaluation of Tocilizumab (Actemra) effects on treatment and clinical symptoms and laboratory signs of ‎Iranian COVID-19 ‎patients Design: This study is a two arm parallel group, double blinded clinical trial in phase 2 which will be carried out on 40 hospitalized ‎COVID-19 patients. Patients randomly divided into two groups (Control group and Tocilizumab group). Settings and conduct: 40 hospitalized COVID-19 patients‎ in Shariati and Imam Khomeini hospitals will be included in this study. Participants/Inclusion and exclusion criteria: Inclusion Criteria: COVID-19 patient confirmed by positive PCR ‎test for SARS-CoV-19 or abnormal CT scan finding (bilateral, sub pleural, peripheral ground glass ‎opacities), Blood oxygen saturation <93% or respiratory rate> 24, high CRP rate or lymphopenia<1100, and not responding to standard COVID-19 treatment.‎ Exclusion criteria: A history of malignancies, positive pro-calcitonin and active infection (Including latent or active TB infection), a history of taking immunosuppressive drugs and corticosteroids Intervention groups: Control group: Will receive only standard treatment for COVID-19 disease. Tocilizumab group: In addition to standard treatment will receive 8mg/kg Tocilizumab. Main outcome variables: Radiographic features findings, Mortality rate, O2 saturation, Need for an oxygen therapy and Laboratory tests